Helus Pharma Inc.
HELP - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$631.62M
Close$
$5.11
51.4% downside
Current Fair Value
51.4% downsideOvervalued by 51.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $631.62 Million |
|---|---|
| Enterprise Value | $465.52 Million |
| Earnings per Share | $-4.23 |
| Beta | 0.54 |
| Outstanding Shares | 52,318,151 |
Return
| Return on Equity | -70.01% |
|---|---|
| Return on Assets | -65.27% |
| Return on Invested Capital | -68.27% |
Valuation & Multiples
| P/E Ratio | -2.42 |
|---|---|
| PEG | -2.71 |
| Price to Sales | - |
| Price to Book Ratio | 2.63 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.82 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.84
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.67
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Cybin Inc
100 employees
CEO: Michael I. Halstead
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer fr...